SAN DIEGO, Nov. 13, 2008 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Lazard Capital Markets Healthcare Conference in New York on Wednesday, November 19, 2008 at 8:30 a.m. ET. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation will be Web cast, and a recording will be made available following the event. The Web cast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live Web cast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.